Study title: Open randomised controlled study to evaluate the safety and immunogenicity of a paediatric dose (0.25 mL) and the standard dose (0.5 mL) of Epaxal® with reference to Havrix Juniror® in healthy children and adolescents (³ 1-16 years) using a 0/6 month schedule.
| Type of medicine: Non-centrally authorised vaccines | |||||
| Therapeutic area: Virus Diseases [C02] | |||||
| Brands: Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: Inactivated hepatitis A virus (strain RG-SB). | |||||
| ATC code: J07BC02 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: EPA 001-T | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | Y | Y | Y | |